Maegim한국어

동국생명과학

303810KOSDAQSector: Pharma & Biotech
₩2,335▲ 1.30%Market cap ₩74.7BAs of Jul 21, 2026 close · updated once daily
B
Grade B65 ptsTop 22% of 2,523 stocks
Financial strength
60.9
Growth momentum
42.5
Price attractiveness
85.8

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

1

Financial strength

60.9
How much debt does it carry relative to equity?
Debt-to-equity ratio
65.7%
✗ Below median · Top 61.2% in sector
Sector median 51.5%
Can it cover what's due within a year?
Current ratio
171.8%
✗ Below median · Top 52.6% in sector
Sector median 191.3%
How much of revenue becomes profit?
Operating margin
10.0%
✓ Above median · Top 19.5% in sector
Sector median -2.3%
How much did it earn on its own capital?
ROE (return on equity)
6.6%
✓ Above median · Top 23% in sector
Sector median -4.5%

Source filing: annual report (separate) — view original ↗

2

Growth momentum

42.5
How much did revenue grow in a year?
Revenue growth (YoY)
-1.1%
✗ Below median · Top 69.2% in sector
Sector median 6.4%
Did core profits grow in a year?
Operating income change (YoY)
9.5%
✓ Above median · Top 45.8% in sector
Sector median 3.6%

Source filing: annual report (separate) — view original ↗

3

Price attractiveness

85.8
Is the price expensive relative to earnings?
P/E (price-to-earnings)
8.6x
✓ Above median · Top 12% in sector
Sector median P/E of profitable peers 14.4x · 57% loss-making
Is the price expensive relative to book value?
P/B (price-to-book)
0.57x
✓ Above median · Top 16.5% in sector
Sector median 1.39x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 248 stocks in Pharma & Biotech

S1A52B66C51D61F15